Neratinib is an oral tyrosine kinase inhibitor used as an adjuvant therapy for patients with HER2-positive early-stage breast cancer following treatment with trastuzumab. By inhibiting the epidermal growth… Read more





















Neratinib is an oral tyrosine kinase inhibitor used as an adjuvant therapy for patients with HER2-positive early-stage breast cancer following treatment with trastuzumab. By inhibiting the epidermal growth factor receptor family, this antineoplastic agent effectively restricts tumor cell proliferation and metastasis. The accompanying range of Neratinib reference standards, including identified impurities, metabolites, and degradation products, is essential for rigorous quality control and method validation in pharmaceutical development. Laboratories rely on these materials for accurate impurity profiling and to support sensitive analytical assays. Stable isotope labelled Neratinib compounds serve as crucial internal standards for quantifying the drug and its related substances in complex biological matrices, ensuring high levels of precision throughout the analytical lifecycle.